DaVita Inc.
21250 Hawthorne Boulevard, Suite 800
Torrance
California
90503
United States
Tel: 310-792-2600
Fax: 310-792-8928
Website: http://www.davita.com/
Email: lzumwalt@davita.com
216 articles with DaVita Inc.
-
DaVita Inc. to Participate in the Bank of America Securities 2022 Healthcare Conference
5/9/2022
DaVita Inc. announced that its chief financial officer, Joel Ackerman, will participate in a fireside chat with investors at the Bank of America Securities 2022 Healthcare Conference on Tuesday, May 10, 2022, at 11 a.m. EDT.
-
DaVita Inc. Schedules 1st Quarter 2022 Investor Conference Call
4/21/2022
DaVita Inc., announced that it will hold its quarterly conference call to discuss first quarter results on Thursday, May 5, 2022, at 5 p.m. Eastern Time.
-
Rockwell Medical Expands Partnership with DaVita
4/11/2022
Rockwell Medical, Inc., a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, announced an expanded partnership with DaVita Inc., a leading kidney care provider.
-
DaVita Inc. 4th Quarter 2021 Results
2/10/2022
DaVita Inc. announced financial and operating results for the quarter and year ended December 31, 2021.
-
DaVita Inc. Schedules 4th Quarter 2021 Investor Conference Call
1/27/2022
DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss fourth quarter results on Thursday, February 10, 2022, at 5:00 p.m. Eastern Time.
-
DaVita Acquires MedSleuth, Deepens Efforts to Improve Transplant Experience
1/18/2022
DaVita Inc. announced its acquisition of transplant software company MedSleuth.
-
The American Diabetes Association® and DaVita Raise Awareness about the Link between Diabetes and Kidney Disease during American Diabetes Month®
11/1/2021
In honor of American Diabetes Month®, the American Diabetes Association® and DaVita are coming together to educate Americans about the connection between diabetes and kidney disease.
-
Miromatrix Announces Key Strategic Investors to Advance the Development of Bioengineered Livers and Kidneys
8/11/2021
Miromatrix Medical Inc., a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save patients' lives and improve quality of life around the world, announced strategic investors involved in its Series C financing, which was followed by its June 24th IPO.
-
Extraordinary Nurses at DaVita Kidney Care Honored with DAISY Awards
5/13/2021
DaVita Kidney Care announced that 60 of its nephrology nurses were honored with The DAISY Award for Extraordinary Nurses® during National Nurses Week.
-
DaVita to Further Elevate its Home Dialysis Care Experience with New Baxter Technology
5/10/2021
DaVita Kidney Care announced the expansion of its home kidney care program to include the HomeChoice Claria Automated Peritoneal Dialysis system enabled by Sharesource remote patient monitoring from Baxter International Inc., a global innovator in renal care.
-
DaVita Inc. 1st Quarter 2021 Results
4/29/2021
For the quarter, diluted earnings per share from continuing operations was $2.09, an increase of 15.5% from the prior year diluted earnings per share from continuing operations and an increase of 14.2% from the prior year adjusted diluted earnings per share from continuing operations.
-
DaVita Solidifies Commitment to ESG, Sets 2025 Goals
4/27/2021
DaVita Inc. announced its 2025 Environmental, Social and Governance goals and released its new ESG reports, bolstering its commitment to corporate citizenship and helping create healthy communities.
-
DaVita Inc. Schedules 1st Quarter 2021 Investor Conference Call
4/22/2021
DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Thursday, April 29, 2021 , at 5:00 p.m. Eastern Time . The company plans to release its results after market close the same day.
-
DaVita Inc. to Participate in the 2021 Barclays Global Healthcare Conference
3/9/2021
DaVita Inc. announced that the company will participate in the 2021 Barclays Global Healthcare Conference.
-
DaVita Inc. Announces Add-On Offering of $750 Million Senior Notes
2/24/2021
DaVita Inc. announced that it has commenced a private add-on offering of $750 million aggregate principal amount of its 4.625% senior notes due June 1, 2030, subject to market and other conditions.
-
DaVita Inc. Announces Upsize and Pricing of Add-On Offering of $1 Billion Senior Notes
2/24/2021
DaVita Inc. (NYSE: DVA) ("DaVita") announced today the upsize and pricing of its previously announced private add-on offering of $750 million aggregate principal amount of its 4.625% senior notes due June 1, 2030 (the "notes").
-
DaVita Inc. 4th Quarter 2020 Results
2/11/2021
[11-February-2021] DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter and year ended December 31, 2020. For the full year diluted earnings per share from continuing operations was $6.39 , an increase of 38.9% from the prior year, and adjusted diluted earnings per share from continuing operations was $7.26
-
DaVita Inc. Schedules 4th Quarter 2020 Investor Conference Call
1/29/2021
DaVita Inc., announced that it will hold its quarterly conference call to discuss fourth quarter results on Thursday, February 11, 2021, at 5:00 p.m. Eastern Time.
-
Early Risk Identification at Core of Innovative Kidney Care Partnership Between Renalytix, DaVita
1/5/2021
First-of-its-kind program combines early risk assessment of kidney decline and comprehensive care management to help slow kidney disease progression, improve care coordination and reduce costs
-
14th Annual Tour DaVita Raises Nearly $1 Million for Bridge of Life
11/23/2020
Event goes virtual in 2020 to raise awareness of kidney health and support global COVID-19 protection efforts